- Home
- MHO vs ACAD Comparison
MHO vs ACAD Comparison
Compare MHO & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHO
- ACAD
- Stock Information
- Founded
- MHO 1976
- ACAD 1993
- Country
- MHO United States
- ACAD United States
- Employees
- MHO N/A
- ACAD N/A
- Industry
- MHO Homebuilding
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- MHO Consumer Discretionary
- ACAD Health Care
- Exchange
- MHO Nasdaq
- ACAD Nasdaq
- Market Cap
- MHO 3.1B
- ACAD 2.8B
- IPO Year
- MHO 1986
- ACAD 2004
- Fundamental
- Price
- MHO $106.19
- ACAD $14.73
- Analyst Decision
- MHO Strong Buy
- ACAD Buy
- Analyst Count
- MHO 3
- ACAD 16
- Target Price
- MHO $168.00
- ACAD $23.93
- AVG Volume (30 Days)
- MHO 276.3K
- ACAD 1.8M
- Earning Date
- MHO 04-23-2025
- ACAD 05-07-2025
- Dividend Yield
- MHO N/A
- ACAD N/A
- EPS Growth
- MHO 21.59
- ACAD N/A
- EPS
- MHO 19.71
- ACAD 1.36
- Revenue
- MHO $4,504,670,000.00
- ACAD $957,797,000.00
- Revenue This Year
- MHO $7.09
- ACAD $13.07
- Revenue Next Year
- MHO $5.18
- ACAD $9.88
- P/E Ratio
- MHO $5.39
- ACAD $10.83
- Revenue Growth
- MHO 11.68
- ACAD 31.85
- 52 Week Low
- MHO $100.22
- ACAD $13.40
- 52 Week High
- MHO $176.18
- ACAD $20.68
- Technical
- Relative Strength Index (RSI)
- MHO 41.03
- ACAD 38.07
- Support Level
- MHO $102.59
- ACAD $14.34
- Resistance Level
- MHO $109.01
- ACAD $15.18
- Average True Range (ATR)
- MHO 6.03
- ACAD 0.80
- MACD
- MHO -0.41
- ACAD -0.02
- Stochastic Oscillator
- MHO 36.81
- ACAD 38.22
About MHO M/I Homes Inc.
M/I Homes Inc is an American construction company that focuses on residential construction. It consists of two distinct operations: homebuilding and financial services. The homebuilding operations are spread into the Midwest, Mid-Atlantic, and Southern regions, and the financial services operations support homebuilding operations by providing mortgage loans and title services to the customers of homebuilding operations. Homebuilding operations comprise a predominant portion of the revenue. The company builds homes and communities that target entry-level, move-up, and luxury homebuyers.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.